Vanguard Capital Management’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
Vanguard Capital Management's ARCT Position: Q3 2026 in Review
Vanguard Capital Management reduced its Arcturus Therapeutics (ARCT) stake by 0.71% in Q3 2026, selling an estimated $82.6K and leaving 1,107,056 shares worth $15.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2541.
Vanguard Capital Management first reported a position in ARCT in Q1 2026 and has held it in 3 quarters since. 155 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.
- Vanguard Capital Management held 1,107,056 shares of Arcturus Therapeutics worth $15.2M as of Q3 2026.
- Vanguard Capital Management sold 7,900 Arcturus Therapeutics shares in Q3 2026, an estimated $82.6K.
- Arcturus Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2541 holding.
- Vanguard Capital Management first reported a position in Arcturus Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 155 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.